Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ALKS – Alkermes plc

Alkermes plc
ALKS
$28.61
Name : Alkermes plc
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $4,717,817,344.00
EPSttm : 2.1
finviz dynamic chart for ALKS
Alkermes plc
$28.61
0.69%
$0.2

Float Short %

6.55

Margin Of Safety %

-7

Put/Call OI Ratio

0.76

EPS Next Q Diff

0.36

EPS Last/This Y

-0.44

EPS This/Next Y

0.01

Price

28.59

Target Price

41.07

Analyst Recom

1.69

Performance Q

-13.85

Relative Volume

0.79

Beta

0.45

Ticker: ALKS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02ALKS31.30.160.906731
2025-06-03ALKS31.260.160.006750
2025-06-04ALKS31.530.160.006750
2025-06-05ALKS30.990.160.166751
2025-06-06ALKS31.70.170.556834
2025-06-09ALKS31.130.170.196848
2025-06-10ALKS31.060.171.256872
2025-06-11ALKS31.210.170.466886
2025-06-12ALKS30.780.1825.606929
2025-06-13ALKS29.830.221.447185
2025-06-16ALKS29.40.230.337290
2025-06-17ALKS29.760.230.037301
2025-06-18ALKS29.410.223.507399
2025-06-20ALKS29.090.230.147421
2025-06-23ALKS29.270.203.906115
2025-06-24ALKS29.270.24135.946420
2025-06-25ALKS28.880.542.077996
2025-06-26ALKS28.830.652.298984
2025-06-27ALKS28.790.6620.449067
2025-06-30ALKS28.690.760.579677
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02ALKS31.30-40.3-136.51.78
2025-06-03ALKS31.27-40.3-144.61.78
2025-06-04ALKS31.53-40.3-141.51.78
2025-06-05ALKS31.00-40.3-150.41.78
2025-06-06ALKS31.72-40.3-136.21.78
2025-06-09ALKS31.14-40.3-150.61.78
2025-06-10ALKS31.08-40.3-145.01.78
2025-06-11ALKS31.20-40.3-142.81.78
2025-06-12ALKS30.78-40.3-149.11.78
2025-06-13ALKS29.82-40.3-155.31.78
2025-06-16ALKS29.41-40.3-149.31.78
2025-06-17ALKS29.77-40.3-140.21.78
2025-06-18ALKS29.33-40.3-149.61.78
2025-06-20ALKS29.09-42.0-136.41.78
2025-06-23ALKS29.27-42.0-131.11.78
2025-06-24ALKS29.34-42.0-132.31.78
2025-06-25ALKS28.88-42.0-139.31.78
2025-06-26ALKS28.83-42.0-134.01.78
2025-06-27ALKS28.81-42.0-133.61.78
2025-06-30ALKS28.59-42.0-136.01.78
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02ALKS-12.902.856.99
2025-06-03ALKS-12.902.856.99
2025-06-04ALKS-13.052.856.99
2025-06-05ALKS-12.752.856.99
2025-06-06ALKS-12.562.856.99
2025-06-09ALKS-12.412.926.99
2025-06-11ALKS-11.202.927.17
2025-06-12ALKS-11.072.927.18
2025-06-13ALKS-11.072.927.18
2025-06-16ALKS-11.072.937.18
2025-06-17ALKS-11.072.937.18
2025-06-18ALKS-11.072.937.18
2025-06-19ALKS-11.072.937.18
2025-06-20ALKS-11.072.937.18
2025-06-24ALKS-11.072.937.18
2025-06-25ALKS-11.072.937.18
2025-06-26ALKS-11.072.936.55
2025-06-27ALKS-11.072.936.55
2025-06-30ALKS-11.072.946.55
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.13

Avg. EPS Est. Current Quarter

0.41

Avg. EPS Est. Next Quarter

0.49

Insider Transactions

-11.07

Institutional Transactions

2.94

Beta

0.45

Average Sales Estimate Current Quarter

342

Average Sales Estimate Next Quarter

355

Fair Value

26.67

Quality Score

99

Growth Score

49

Sentiment Score

46

Actual DrawDown %

21.6

Max Drawdown 5-Year %

-33.2

Target Price

41.07

P/E

13.62

Forward P/E

16.08

PEG

P/S

3.12

P/B

3.12

P/Free Cash Flow

9.8

EPS

2.1

Average EPS Est. Cur. Y​

1.78

EPS Next Y. (Est.)

1.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

23.3

Relative Volume

0.79

Return on Equity vs Sector %

-0.5

Return on Equity vs Industry %

15.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-136
Alkermes plc
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
stock quote shares ALKS – Alkermes plc Stock Price stock today
news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALKS – Alkermes plc yahoo finance google finance
stock history ALKS – Alkermes plc invest stock market
stock prices ALKS premarket after hours
ticker ALKS fair value insiders trading